Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2018

FDA fast tracks MedyMatch’s brain bleed detection software

The US Food and Drug Administration (FDA) has granted expedited access pathway (EAP) / breakthrough device designation to Israeli firm MedyMatch Technology’s artificial intelligence (AI) based software designed to detect intracranial haemorrhage (ICH).

The US Food and Drug Administration (FDA) has granted expedited access pathway (EAP) / breakthrough device designation to Israeli firm MedyMatch Technology’s artificial intelligence (AI) based software designed to detect intracranial haemorrhage (ICH).

The software leverages deep learning technologies to automatically analyse non-contrast head CT images, which are considered as the standard for initial assessment of possible ICH in emergency medicine settings.

Said to be sensitive to the presence of ICH in these scans, the AI software will notify the physician upon detection of a bleed.

MedyMatch Clinical, Regulatory and Quality Affairs vice-president Dr Joshua Schulman said: “FDA’s Expedited Access Pathway and Breakthrough Device designation gives us the opportunity to accelerate the development and approval process of our intracranial haemorrhage software in the US.

“The firm’s machine vision and deep learning platform is intended to support evaluation of various clinical indications.”

“This designation is recognition of both the need for new assessment tools for intracranial haemorrhage and an affirmation of MedyMatch’s technical approach to assisting clinicians who need to make time-sensitive yet accurate decisions in emergency settings.”

The firm’s machine vision and deep learning platform is intended to support evaluation of various clinical indications.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

A team of AI, deep learning, and machine vision experts from MedyMatch have collaborated with clinical and industry partners to gain an understanding of medical data and use it for different medical applications such as the identification of ICH.

MedyMatch chairman and CEO Gene Saragnese said: “As the population grows older and lives longer and as more treatment options become available, MedyMatch is positioned to assist clinicians in making assessments that can ultimately save lives and minimise disability while utilising healthcare resources in the best way possible.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU